Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
| ▸ | HRH1 | P35367 | 1/20 | 0.56 |
| ▸ | ATP4A | P20648 | 4/20 | 0.54 |
| ▸ | ATP4B | P51164 | 4/20 | 0.54 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL236995 | 0.84 | HRH3 (0.60) | HRH3KCNH2 | |
| SCHEMBL240840 | 0.80 | HRH3 (0.53) | HRH3KCNH2HRH1ATP4AATP4B | |
| SCHEMBL239160 | 0.79 | NPC1 (0.61) | HRH3KCNH2HRH1ATP4AATP4B | |
| SCHEMBL239175 | 0.78 | HRH3 (0.58) | HRH3KCNH2HRH1ATP4AATP4B | |
| SCHEMBL236973 | 0.77 | HRH3 (0.67) | HRH3KCNH2HRH1ATP4AATP4B | |
| SCHEMBL241610 | 0.76 | LTA4H (0.57) | HRH3KCNH2HRH1ATP4AATP4B | |
| SCHEMBL239215 | 0.75 | HRH3 (0.65) | HRH3KCNH2HRH1 | |
| SCHEMBL2757806 | 0.74 | HRH3 (0.63) | HRH3KCNH2HRH1HRH4 | |
| SCHEMBL491626 | 0.74 | HRH3 (1.00) | HRH3KCNH2HRH1HRH4NPC1 | |
| SCHEMBL4094594 | 0.72 | HRH3 (1.00) | HRH3KCNH2HRH1HRH4NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912183-B2 | Substituted pyridazine derivatives | CEPHALON, INC. (US) | 2014-12-16 | — | — | US | claimed |
| EP-2252593-B1 | SUBSTITUTED PYRIDAZINE DERIVATIVES WHICH HAVE HISTAMINE H3 ANTAGONIST ACTIVITY | CEPHALON INC (US) | 2014-04-23 | — | — | EP | claimed |
| US-20120004231-A1 | Substituted Pyridazine Derivatives | CEPHALON, INC. (US) | 2012-01-05 | — | — | US | claimed |
| US-8076331-B2 | Substituted pyridazine derivatives | CEPHALON, INC. (US) | 2011-12-13 | — | — | US | claimed |
| US-20100311752-A1 | Substituted pyridazine derivatives | CEPHALON, INC. (US) | 2010-12-09 | — | — | US | claimed |
| US-8912183-B2 | Substituted pyridazine derivatives | CEPHALON, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912183-B2 | Substituted pyridazine derivatives | CEPHALON, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912183-B2 | Substituted pyridazine derivatives | CEPHALON, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| EP-2752406-A1 | Substituted pyridazine derivatives which have histamine H3 antagonist activity | CEPHALON, INC. (US) | 2014-07-09 | — | — | EP | disclosed |
| EP-2252593-B1 | SUBSTITUTED PYRIDAZINE DERIVATIVES WHICH HAVE HISTAMINE H3 ANTAGONIST ACTIVITY | CEPHALON INC (US) | 2014-04-23 | — | — | EP | disclosed |
| EP-2252593-B1 | SUBSTITUTED PYRIDAZINE DERIVATIVES WHICH HAVE HISTAMINE H3 ANTAGONIST ACTIVITY | CEPHALON INC (US) | 2014-04-23 | — | — | EP | disclosed |
| US-20120004231-A1 | Substituted Pyridazine Derivatives | CEPHALON, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004231-A1 | Substituted Pyridazine Derivatives | CEPHALON, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-8076331-B2 | Substituted pyridazine derivatives | CEPHALON, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076331-B2 | Substituted pyridazine derivatives | CEPHALON, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076331-B2 | Substituted pyridazine derivatives | CEPHALON, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20100311752-A1 | Substituted pyridazine derivatives | CEPHALON, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100311752-A1 | Substituted pyridazine derivatives | CEPHALON, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100311752-A1 | Substituted pyridazine derivatives | CEPHALON, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| WO-2009097306-A1 | SUBSTITUTED PYRIDAZINE DERIVATIVES WHICH HAVE HISTAMINE H3 ANTAGONIST ACTIVITY | CEPHALON, INC. (US) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004231-A1 | Substituted Pyridazine Derivatives | HRH3, HRH4, HRH2 | HRH3 1/4885KCNH2 390/4885HRH1 4/4885 |
| US-20100311752-A1 | Substituted pyridazine derivatives | HRH3, HRH4, HRH2 | HRH3 1/4885KCNH2 390/4885HRH1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.